echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Medical insurance catalog + volume purchase double pressure, foreign companies still have room to drop drug prices

    Medical insurance catalog + volume purchase double pressure, foreign companies still have room to drop drug prices

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, China's regulatory policies have effectively regulated the unreasonable pricing behavior of large pharmaceutical companies in the Chinese market, and national medical insurance negotiations and volume purchases have also enabled foreign pharmaceutical companies to effectively control drug prices


    Foreign pharmaceutical companies actively seek to be included in the national medical insurance catalog

    Foreign pharmaceutical companies actively seek to be included in the national medical insurance catalog

    In the first half of this year, AstraZeneca’s sales in mainland China increased by 11% at a constant exchange rate to US$3.


    Frank Clyburn, president of Merck's human health in the company's most recent quarterly conference call, performance growth, "driven mainly by Gardasil"


    Another company that has benefited from its recent inclusion in the National Medical Insurance Catalog is Novartis


    Eli Lilly’s Chief Financial Officer Anat Ashkenazi said that “due to the significant acceleration in sales of new drugs in the past three quarters,” Eli Lilly achieved a 35% growth in the Chinese market in the second quarter


    Volume purchases further effectively supervise high pricing

    Volume purchases further effectively supervise high pricing

    In order to reduce the cost of medicines, China launched a new plan in 2018 to reduce the prices of generic medicines


    In response to this, many foreign pharmaceutical companies have begun to divest the rights of drugs in mainland China to other companies


    In July, the National Medical Security Administration of China convened insulin developers to discuss a centralized procurement plan for key diabetes drug categories


    Under the new policy, the unreasonable pricing behavior of foreign pharmaceutical companies in the past has been effectively supervised.


    Reference source: Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering.


    Reference source: Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering.
    But anxiety grows over outlook for biologics
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.